pregnant and lactating mothers. Training in various skills is being imparted to the affected families and worksheds have been set up to provide employment opportunities. Banks have sanctioned loans to 3775 gas affected persons under special Training and Employment Programme for Urban Poor (STEPUP). Therefore, the question of restoring distribution of free rations does not arise.

Report of the Technical team about M/s. Glaxo

689. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1770 given in the Rajya Sabha on the 12th August, 1985 and state:

(a) when the Technical Team submitted its report about the findings of unauthorised installation of plant and machinery by M|s. Glaxo;

(b) what are the details of the findings of the Technical Team;

(c) whether Government have taken any final decision thereon; and

(d) if so, what are the details thereof in this regard?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The Technical Team submitted its reports in July, 1984 (Bathamethasone) and September, 1984 (Formulations).

(b) to (d) The reports of the Technical Team have been examined. In the light of the overall Industrial policy of the Government it has been decided to re-endorse|recognise the capacities in accordance with the various schemes announced by the Government from time to time.

Manufacture of phexin capsules

690. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1798 given in the Rajya Sabha on the 12th August, 1985 and state:

(a) what is the price at which each pack and strength of Phexin capsules is being supplied by Capsulation Services Limited to Glaxo and what price Glaxo is charging from the consumers;

(b) whether it is a fact that Glaxo has been permitted to manufacture Phexin Capsules from indigenous bulk drugs; if so, how Government have allowed them to get these capsules manufactured by Capsulation Services Limited from imported bulk drug; and

(c) what are the reasons for the same?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Prices at which M|s. Capsulation Services Limited are supplying Phexin Capsules to M|s. Glaxo Laboratories (India) Limited are not available. Capsulation Services Limited are having marketing arrangements with M|s Glaxo Laboratories (India) Limited. Maximum retail price charged by M|s. Glaxo Laboratories (India) Limited for these capsules are given below:—

1.	Phexin Capsules	250 mg./Cap. 10's Rs. 30.27
2.	Phexin Capsules	500 mg./Cap. 10's Rs. 58.79

(b) and (c) M/s. Glaxo Laboratories (India) Limited hold a letter

of intent for the production of Cephalexin and its formulations. For marketing formulations produced by other companies, M|s. Glaxo Laboratories (India) Limited do not require any permission from the Government.

Equity of M/s. John Wyeth and Brothers

691. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 627 given in the Rajya Sabha on the 29th July, 1985 and state:

(a) what was the original equity of M|s. John Wyeth and Bros. Ltd. and what is the present foreign equity and when did this company diluted its foreign equity;

(b) the names of financial and public institutions to whom shareholdings were passed on while diluting the foreign equity alongwith present shareholding of each in this company:

(c) how much percentage of share holdings have been given to individuals alongwith names and present shareholdings of each;

(d) who are the Directors and Managing Director of this company and whether any one of them has any connections with any other drug company; and

(e) if so, the names of other companies alongwith present status and what is the interest in each?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M/s. John Wyeth & Brothers Ltd. was branch in India of a U.K. based company. They were granted Reserve Bank of India's approval on 11-10-1983 for transfer of the business to M|s. John Wyeth (India) Pvt. Ltd.

(b) and (c) M/s. John Wyeth (India) have not disinvested the equity holding in favour of financial institution or resident Indians.

(d) and (e) The relevant information as furnished by the company is given in the Annexure;

Annexure

Name of Directors	Connection with other Drug Companies
A. Singh – Managing Director	Chairman – Wyeth Laboratories Limited
J.R. Stafford	President – American Home Products.
S.N. Talwar	E. Merck (India) Limited. Johnson & Johnson Limited.
A.S. Mehta	Technical Director – Wyeth Laboratories Limited.
D.C. Shroff	Fulford (India) Limited. Bayer (India) Limited.
K.K. Maheshwari	Advisor – Geoffrey Manners & Company Limited.
M.K. Maheshwari	General Manager – Marketing Consumer Products. Geoffrey Manners and Co. Ltd.
J.N. Mallaya	General Manager Materials Planning and Exports. Geoffrey Manners and Co. Ltd.
S.S. Reen	Director Production Control Wyeth Laboratories Limited.